



The effect of perioperative blood transfusion on oncological outcomes in radical cystectomy patients: a narrative review

Stefania Zamboni^{1,2#}, Chiara Lonati^{1,2#}, Carlotta Palumbo^{1,2}, Maria Cristina Marconi^{1,2},
Francesca Mondini^{1,2}, Marco Lattarulo^{1,2}, Marco Moschini³, Luca Cristinelli^{1,2}, Sandra Belotti^{1,2},
Claudio Simeone^{1,2}

¹Urology Unit, ASST Spedali Civili, Brescia, Italy; ²Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy; ³Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland

Contributions: (I) Conception and design: C Lonati, S Zamboni, C Simeone; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Lonati, S Zamboni, MC Marconi, F Mondini, M Moschini, M Lattarulo, C Palumbo; (V) Data analysis and interpretation: C Lonati, S Zamboni, L Cristinelli, S Belotti; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work and shared first authorship.

Correspondence to: Stefania Zamboni, MD. Urology Unit, ASST Spedali Civili, Brescia, Italy; Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia 25123, Italy. Email: stefania.zamboni@libero.it.

Abstract: In the last few years, the role of allogeneic blood transfusions (ABTs) on oncological outcomes in patients treated with surgery for various malignancies (i.e., colorectal, kidney and prostate cancer) has been evaluated in several studies. However, only a few data exist regarding the role of transfusions in bladder cancer (BCa) patients treated with radical cystectomy (RC) and results reported in literature are controversial. Therefore, our narrative review aims to summarize the current studies evaluating the complex relationship between perioperative ABT and oncological outcomes in patients who underwent RC for BCa.

Keywords: Bladder cancer (BCa); radical cystectomy (RC); perioperative blood transfusions

Received: 07 December 2019; Accepted: 31 January 2020; Published: 25 June 2020.

doi: 10.21037/amj.2020.02.03

View this article at: <http://dx.doi.org/10.21037/amj.2020.02.03>

Introduction

Bladder cancer (BCa) is the 6th most common cancer worldwide (1), the second in the genitourinary system with an estimated 80,470 new cases in 2019, and the 9th leading cause of cancer death (2). The majority of BCa is diagnosed after the occurrence of haematuria, with 75% of patients who presents a non-muscle invasive disease (3). However, these patients have a high risk of recurrence (50% of cases) and 20% of risk of progression at 5 years (4). Radical cystectomy (RC) with bilateral pelvic lymph node dissection (PLND) (3) represents the standard of care of very high-risk non-muscle invasive BCa and of muscle-invasive BCa. Nowadays, open radical cystectomy (ORC) is the most commonly performed surgical technique: however, in the last decade, minimally invasive surgical

approaches including laparoscopic (LRC) or robotic radical cystectomy (RARC) (5) have spread worldwide. Although the introduction of these procedures, RC remains a complex surgery, burdened by high rates of perioperative morbidity and mortality: about 60% of the cases suffers from at least one complication within 90 days after surgery (6), and 30- and 90-day postoperative mortality rates are around 3% and 7%, respectively (7). Among the most common complications, there is intraoperative bleeding, which can require or not blood transfusions (BTs). This complication could be attributed to two main factors: first of all, to the technical complexity of the procedure and, secondly, to patients' population which usually includes elderly patients with significant comorbidities. Moreover, the neoplasm itself can bleed, causing preoperative anaemia which can increase the risk of postoperative complications

and the need of transfusions. Perioperative transfusion rate in patients undergoing RC is around 60% (8,9). Several studies suggested that perioperative BTs might have an impact on survival outcomes in RC patients but results reported in literature are controversial. For this reason, we sought to review the current available studies to evaluate the association between allogeneic blood transfusions (ABTs) and survival outcomes in patients treated with RC and PLND with curative intent for BCa.

Evidence acquisition

We searched the Medline/PubMed database using individual or/and different combinations of terms including: “bladder cancer”, “urothelial carcinoma of the bladder”, “radical cystectomy”, “perioperative blood transfusion”, “cancer recurrence”, “survival”, “oncological outcomes” and “mortality”. Only title and abstract in English language were screened for eligibility: if included, the full text was analyzed. Our research included original article and meta-analyses from 2012 to 2019.

The effect of transfusion in surgical patients

Despite the potential life-saving role, BTs could be related to significant complications including transfusion-associated lung injury (TRALI), transmission of infections, and allergic reactions. For these reasons, over the past 40 years, several studies focused their attention on the effect of ABT in patients treated with surgery, identifying both proinflammatory and immunosuppressive effects. The first observations date back in 1973, when Opelz *et al.* (10) reported improved survival rates in renal-transplanted patients who received ABT compared to those who did not. Other observational studies underlined a role of ABT in decreasing the risk of recurrence in autoimmune disorders (such as Crohn’s disease) (11) and in spontaneous abortions in women with a history of recurrent abortions (12). On the other side, this immunosuppressive role can lead to deleterious effects: in 1981 Gantt *et al.* (13) suggested a possible association between ABT and increased risk of cancer recurrence and metastases due to the dysregulated recipient’s immune system. Other harmful effects include an increased risk of postoperative bacterial infections (14) and activation of latent CMV and HIV infections (15).

Several studies tried to clarify the mechanisms of transfusion-related immunomodulation (TRIM) (16). The TRIM effect is mediated by: (I) immunologically active

white blood cells (WBC) that downregulate the recipient’s immune system by shifting to immunosuppressive Lymphocytes Th2 responses (17); (II) soluble WBC-derived mediators that induce innate immune cell apoptosis and decrease natural killer cell activity (18); (III) platelet (PLT) and PLT-derived factors; (IV) heme and iron derived by aged and damaged red blood cell (RBC) (named as “storage lesions”) (19); finally (V) ubiquitin and (VI) extracellular vesicle (EV) counts which increase with storage duration (20). This mechanism is depicted in *Figure 1*.

Moreover, the intra-operative release of circulating tumor cells caused by surgical manipulation (21) and the decrease of host’s immune system due to anaesthetics and opioids (22), could have an impact on oncological outcomes in patients treated with perioperative blood transfusions. These association between ABT and worse survival has been investigated in various malignancies, such as colorectal (23), hepatic (24), esophageal (25) and pancreatic cancer (26). In the urological field, contradictory data have been reported among patients with kidney (27,28), prostate (29,30) and BCa and the impact of ABT in these cancers is not yet clarified.

The oncological effect of transfusion in patients who underwent RC

The studies evaluating the effect of perioperative ABT in BCa patients treated with RC are summarized in *Table 1*. Linder *et al.* (8) in 2013 analyzed 2,060 patients treated with RC: of them, 1,279 received ABT (62%). At multivariable analyses ABT was found associated with an increased risk of tumor recurrence [hazard ratio (HR): 1.20, confidence interval 95% (CI): 1.01–1.42; P value =0.04], of cancer-specific mortality (HR: 1.31, 95% CI: 1.10–1.57; P=0.003) and of all-causes mortality (HR: 1.27, 95% CI: 1.12–1.45; P=0.0002). Similar results were reported by Buchner *et al.* (31) who analyzed a cohort of patients treated with RC in a retrospective single-center study. Of the 722 patients included in the analyses, 473 received ABT which was found significantly associated with a decreased cancer-specific survival (HR: 1.11, 95% CI: 1.06–1.16; P<0.001). The authors performed a sub-analysis, dividing BT into two groups: intraoperative blood transfusion (IBT) and postoperative blood transfusion (PBT): both variables remained significantly associated with reduced cancer specific survival with an HR: 1.08, 95% CI: 1.01–1.15; P=0.23 for IBT and an HR: 1.14, 95% CI: 1.07–1.21; P<0.001 for PBT. Similarly, Syan-Bhanvadia *et al.* (32)




Figure 1 Mechanisms of transfusion-related immunomodulation (TRIM).

found an association between ABT and reduced recurrence-free survival (HR: 2.16, 95% CI: 1.13–41.12; P=0.02) and overall survival (HR 2.25, 95% CI: 1.25–4.88; P=0.01). The authors also suggested a restrictive transfusion protocol which could be safer for patients treated with RC. Similar results were reported in Siemens *et al.* study (33), in which 2,593 patients who underwent RC between 2000 and 2008 were analyzed. Of them, 62% received ABT which was found associated with worse overall survival (HR: 1.33, 95% CI: 1.20–1.48; P<0.001) and cancer-specific survival at 5 years (HR: 1.39, 95% CI: 1.23–1.56; P<0.001).

However, Morgan *et al.* (34) reported conflicting results, depending on the statistical method used for the analyses: in a non-transformed model (in which continuous variables were assumed to have linear relationships with the outcomes), the authors found that ABT (n=323, 41.6%) was associated with a significant higher risk of overall mortality (HR: 1.17; P=0.04). On the contrary, in the second model (a restricted cubic splines model for nonlinear relationships) no association was found between them (HR: 1.03; P=0.29). Soubra *et al.* (35) analyzed the relationship between ABT and mortality in patients who underwent surgical treatment for major urologic cancers,

such as bladder, prostate and kidney cancer. In the BCa cohort, the authors reported a significant association between ABT and increased all-causes mortality (HR: 1.109, 95% CI: 1.011–1.21; P=0.028), whereas no significant association between ABT and cancer-specific mortality was reported (HR: 1.052, 95% CI: 0.919–1.204; P=0.4648). Kluth *et al.* (36), in a multicenter retrospective study, did not find an association between ABT and worse oncological outcomes in the multivariable analysis (disease recurrence p = 0.06, cancer-specific mortality P=0.17, any-cause mortality P=0.07). Similarly, in a retrospective single-center study, Lee *et al.* (37) compared patients who received ABT (315, 73% of all patients) to those who did not and no significant association was found between ABT and overall survival in the multivariable analysis (HR: 1.56, 95% CI: 0.98–2.48; P=0.058). Similarly, Vetterlein *et al.* (38) recorded data from 611 patients underwent RC in 2011, of whom 315 (52%) received ABT. The authors found that ABT was not an independent predictor of oncological outcomes, including disease recurrence (HR: 0.96, 95% CI: 0.54–1.70; P=0.9), overall survival (HR: 1.34, 95% CI: 0.90–1.99; P=0.2), cancer-specific mortality (sub-hazard ratio (SHR):1.03, 95% CI: 0.57–1.87; P>0.9) and other-

cause mortality (SHR: 2.16, 95% CI: 0.99–4.74; P=0.054).

Finally, there are only two systematic reviews, published by Wang *et al.* (44) in 2015 and by Cata *et al.* (45) in 2016. In the first meta-analysis ABT was an independent factor

to predict all-causes mortality, cancer-specific mortality and cancer recurrence. Similarly, Cata *et al.* (45) found a significant association between ABT and cancer-specific survival, overall survival and recurrence-free survival.

Table 1 Summary of studies evaluating the effect of perioperative allogeneic blood transfusion on survival outcomes in patients who underwent radical cystectomy for bladder cancer

Study	Year of publication	Study design	Number of patients	Transfusion group, n (%)	FU (months)	Type of analysis	Outcomes	Results	P value
Linder <i>et al.</i> (8)	2013	Retrospective, single-center	2,060	1,279 (62%)	131	MVA cox regression analysis	CSM; OM; recurrence	HR: 1.31, CI: 1.10–1.57 HR: 1.27, CI: 1.12–1.45 HR: 1.20, CI: 1.01–1.42	0.003 0.0002 0.04
Gierth <i>et al.</i> (9)	2014	Retrospective, single-center	350	Overall 219 (63%): 183 IBT; 99 PBT; 63 IBT + PBT	70	MVA cox regression analysis	RFS for IBT; RFS for PBT; OS for IPB; OS for PBT	HR: 1.50, CI: 1.27–1.77 HR: 1.56, CI: 1.30–1.88 HR: 1.77, CI: 1.47–2.13 HR: 1.76, CI: 1.41–2.21	<0.001 <0.001 <0.001 <0.001
Buchner <i>et al.</i> (31)	2017	Retrospective, single-center	722	Overall 473 (66%): 263 IBT; 132 PBT; 78 IBT + PBT	26	MVA cox regression analysis	CSS for IBT; CSS for PBT	HR: 1.08, CI: 1.01–1.15 HR: 1.14, CI: 1.07–1.21	0.23 <0.001
Syan-Bhanvadia <i>et al.</i> (32)	2017	Prospective, single-center	173	46 (27%)	37	MVA cox regression analysis	RFS; OS	HR: 2.16, CI: 1.13–41.12 HR: 2.25, CI: 1.25–4.88	0.02 0.01
Siemens <i>et al.</i> (33)	2017	Retrospective, single-center	2,593	1,608 (62%)	–	MVA cox regression analysis	CSS; OS	HR: 1.33, CI: 1.20–1.48 HR: 1.39, CI: 1.23–1.56	<0.001 <0.001
Morgan <i>et al.</i> (34)	2013	Retrospective, single-center	777	323 (42%)	25.0	Non-transformed model; Restricted cubic splines model	OM	HR: 1.17, CI: 1.01–1.36 HR: 1.03, CI: 0.77–1.37	0.04 0.29
Soubra <i>et al.</i> (35)	2015	Retrospective, multicenter	5,462	1,116 (20%)	21	MVA cox regression analysis	CSM; OM	HR: 1.05, CI: 0.91–1.20 HR: 1.10, CI: 1.01–1.21	0.4 0.02

Table 1 (continued)

Table 1 (continued)

Study	Year of publication	Study design	Number of patients	Transfusion group, n (%)	FU (months)	Type of analysis	Outcomes	Results	P value
Kluth <i>et al.</i> (36)	2014	Retrospective, multicenter	2,895	1,128 (39%)	36.1	MVA cox regression analysis	CSM; OM; recurrence	HR: 1.10, CI: 0.96–1.27	0.17
								HR: 1.10, CI: 0.99–1.22	0.07
								HR: 1.13, CI: 0.99–1.28	0.06
Lee <i>et al.</i> (37)	2015	Retrospective, single-center	432	315 (73%)	39.5	MVA cox regression analysis	OS	HR: 1.56, CI: 0.98–2.48	0.058
Vetterlein <i>et al.</i> (38)	2018	Prospective, single-center	611	315 (52%)	26	MVA cox regression analysis and MVA competing-risk analysis	CSM; OS; recurrence	SHR: 1.03, CI: 0.57–1.87	>0.9
								HR: 1.34, CI: 0.90–1.99	0.02
								HR: 0.96, CI: 0.54–1.70	0.9
Abel <i>et al.</i> (39)	2014	Retrospective, multicenter	360 (UW); 1,770 (Mayo Clinic)	Overall 241 (67%): 66 IBT; 79 PBT; 98 IBT + PBT. Overall 1,100 (62%): 414 IBT; 285 only PBT; 401 IBT + PBT	18.7; 132	MVA cox regression analysis	CSM for IBT; CSM for PBT; OM for IBT; OM for PBT; Recurrence for IBT; Recurrence for PBT. CSM for IBT; CSM for PBT; OM for IBT; OM for PBT; Recurrence for IBT; Recurrence for PBT	HR: 1.49, CI: 1.00–2.25	0.056
								HR: 0.91, CI: 0.54–1.53	0.7
								HR: 1.40, CI: 1.20–1.62	<0.0001
								HR: 1.06, CI: 0.88–1.27	0.56
								HR: 1.45, CI: 0.84–2.5	0.18
								HR: 1.11, CI: 0.69–1.19	0.76
								HR: 1.55, CI: 1.24–1.94	0.0001
								HR: 0.89, CI: 0.67–1.18	0.41
								HR: 1.40, CI: 1.20–1.62	<0.0001
								HR: 1.06, CI: 0.88–1.27	0.56
HR: 1.4, CI: 1.16–1.81	0.001								
HR: 0.91, CI: 0.68–1.20	0.49								

Table 1 (continued)

Table 1 (continued)

Study	Year of publication	Study design	Number of patients	Transfusion group, n (%)	FU (months)	Type of analysis	Outcomes	Results	P value
Moschini <i>et al.</i> (40)	2015	Retrospective, single-center	1,490	Overall 580 (39%): 322 IBT 97 PBT 161 IBT + PBT	125	MVA cox regression analysis	Recurrence for IBT; Recurrence for PBT; CSM for IBT; CSM for PBT; OM for IBT; OM for PBT	HR: 1.24, CI: 1.03–1.65 HR: 1.50, CI: 0.78–2.89 HR: 1.60, CI: 1.20–2.26 HR: 1.60, CI: 0.81–3.17 HR: 1.45, CI: 1.02–2.08 HR: 1.36, CI: 0.72–2.60	0.04 0.5 0.02 0.2 0.03 0.4
Moschini <i>et al.</i> (41)	2016	Retrospective, single-center	728	–	97	MVA cox regression analysis	Recurrence for IBT; Recurrence for PBT	HR: 1.43, CI: 1.15–1.97 HR: 1.83, CI: 0.92–3.01	0.03 0.1
Moschini <i>et al.</i> (42)	2017	Retrospective, single-center	1,081 (testing cohort); 433 (validation cohort)	Overall 445 (42%): 274 IBT; 76 PBT; 122 IBT + PBT. Overall 183 (42%): 122 IBT; 28 PBT; 28 IBT + PBT.	52; 83	MVA cox regression analysis	Distant recurrence for IBT; Distant recurrence for PBT; Distant recurrence for IBT; Distant recurrence for PBT	HR: 1.15, CI: 0.74–1.78 HR: 1.32, CI: 0.84–2.05 HR: 1.22, CI: 0.6–2.46 HR: 1.55, CI: 0.84–2–87	0.5 0.2 0.6 0.4
Sadeghi <i>et al.</i> (43)	2012	Retrospective, single-center	638	209 (33%)	25.5	MVA cox regression analysis	CSS OS	HR: 1.2, CI: 0.85–1.69 HR: 1.15, CI: 0.91–1.45	0.3 0.246

FU, follow up; MVA, multivariable; CSM, cancer-specific mortality; HR, hazard ratio; CI, confidence interval; OM, overall mortality; IBT, intraoperative blood transfusion; PBT, postoperative blood transfusion; RFS, recurrence-free survival; OS, overall survival; CSS, cancer-specific survival; SBH, sub-hazard ratio.

Effect of timing of blood transfusion on survival

Few data exist regarding the role of the timing of ABT, considered as IBT or PBT.

Gierth *et al.* (9) collected data from 350 patients treated with RC. Overall, 219 patients were treated with ABT and 183 (52%) received IBT, whereas 99 (28%) PBT. The authors showed that both IBT and PBT are significant independent predictor of progression-free survival (HR: 1.50, 95% CI: 1.27–1.77; $P < 0.001$ and HR: 1.56, 95% CI: 1.30–1.88; $P < 0.001$ for IBT and PBT, respectively)

and overall survival (HR: 1.77, 95% CI: 1.47–2.13; $P < 0.001$ and HR: 1.76, 95% CI: 1.41–2.21; $P < 0.001$ for IBT and PBT, respectively). On the contrary, Buchner *et al.* (31) reported that PBT was associated with a decrease in cancer-specific survival (HR: 1.14, 95% CI: 1.07–1.21; $P < 0.001$), whereas IBT was not significant (HR: 1.08, 95% CI: 1.01–1.15; $P = 0.23$). Abel *et al.* analyzed two different cohorts of patients treated with RC: a primary cohort of 360 patients from University of Wisconsin (UW) and a validation cohort of 1,770 patients from Mayo Clinic and

patients were divided into a group which received IBT and a group which received PBT. In the primary cohort, the authors found that IBT was an independent risk factor for cancer-specific mortality (HR: 1.77, 95% CI: 1.06–2.94; $P=0.03$), while PBT was not associated with worse survival outcomes. No significant relationship was found for intra and PBT regarding tumor recurrence and all-causes mortality in the same cohort. Moreover, in the validation cohort from Mayo Clinic, IBT was found associated with a significant higher risk of tumor recurrence (HR: 1.45, 95% CI: 1.16–1.81; $P=0.001$), cancer-specific mortality (HR: 1.55, 95% CI 1.24–1.94; $P=0.0001$) and all-causes mortality (HR: 1.40, 95% CI: 1.20–1.62; $P<0.0001$), while PBT was not associated with worsening prognosis. Similarly, Moschini *et al.* (40) recorded data from 1,490 patients who underwent RC between 1990 and 2013. Of them, 322 patients received IBT, 97 received PBT and 161 received both IBT and PBT. In the multivariable analysis patients who received IBT and both IBT and PBT were combined in a single group. The authors found that IBT was an independent risk factor for cancer-specific mortality (HR: 1.6, 95% CI: 1.20–2.26; $P=0.02$), all-causes mortality (HR: 1.45, 95% CI: 1.02–2.08; $P=0.03$) and tumor recurrence (HR: 1.24, 95% CI: 1.03–1.65; $P=0.04$). On the contrary, the administration of PBT was not associated with worse oncological outcomes. The same result was found in another study (41), in which IBT was found significantly associated with cancer-specific mortality and overall mortality, whereas no association was found for PBT ($P>0.05$). Moreover, Moschini *et al.* (42) in another study, evaluated the risk of distant recurrence after RC in two independent cohorts of patients (testing and validation cohort), considering patients according timing of administration of ABT (IBT *vs.* PBT). In both cohorts, timing of BT was not significantly related to an increased risk of distant recurrence (all $P\geq 0.2$).

Number of units transfused

Only a few studies investigated the relationship between number of units transfused and survival outcomes of patients treated with RC.

Linder *et al.* (8) found a positive association between number of units transfused and increased risk of cancer-specific mortality (HR: 1.07; $P<0.0001$) and all-causes mortality (HR 1.05; $P<0.0001$): each blood's unit received was associated with a 7% increased risk of cancer-specific mortality. Likewise, Lee *et al.* (37) recorded that an

increased number of units transfused (i.e., >4 units) was a significant independent predictor of overall survival (HR: 1.69, 95% CI: 1.15–2.49; $P=0.007$). Abel *et al.* (39) reported that among patients who received an IBT in the primary cohort from University of Wisconsin, each unit transfused conferred a 17% increased risk of cancer-specific mortality (HR: 1.17, 95% CI: 1.03–1.32; $P=0.01$), whereas no association was found among patients who received PBT in the same cohort (HR: 1.05, 95% CI: 0.72–1.54; $P=0.8$). Similar results were reported for the validation cohort from Mayo Clinic (HR: 1.07, 95% CI: 1.03–1.11; $P=0.0001$ for IBT and HR: 0.92, 95% CI: 0.79–1.06; $P=0.26$ for PBT). Similarly, Gierth *et al.* (9) found a worse prognosis in terms of progression-free survival and overall survival the more blood units were transfused ($P<0.001$ for IBT and PBT).

On the contrary, Sadeghi *et al.* (43) analyzed data from 638 patients: of them 209 (33%) received ABT. On multivariable analysis the number of units transfused was not an independent factor to predict cancer-specific survival ($P=0.3$) and overall survival ($P=0.246$). In Moschini *et al.* (42) study, the number of unit transfused was not found associated with an increased risk of distant recurrence.

Conclusions

RC represents a complex surgery, which often requires BTs. Several studies have investigated the effects of perioperative blood transfusions in patients with BCa treated with RC, especially in terms of oncological outcomes, investigating also the correct timing of perioperative blood transfusions. Unfortunately, the relationship between ABT and survival outcomes is still unclear, with contrasting results reported in literature: further studies are needed to explain this complex relationship in order to address the medical practice to an individualized treatment and to improve prognosis of these fragile patients.

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related

to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

1. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. *Eur Urol* 2017;71:96-108.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019;69:7-34.
3. Alfred Witjes J, Lebre T, Comp erat EM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. *Eur Urol* 2017;71:462-75.
4. Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Gu erin. *Eur Urol* 2016;69:60-9.
5. Zamboni S, Soria F, Mathieu R, et al. Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. *BJU Int* 2019. [Epub ahead of print].
6. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. *Eur Urol* 2009;55:164-74.
7. Hanna N, Leow JJ, Sun M, et al. Comparative effectiveness of robot-assisted vs. open radical cystectomy. *Urol Oncol* 2018;36:88.e1-88.e9.
8. Linder BJ, Frank I, Chevill e JC, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. *Eur Urol* 2013;63:839-45.
9. Gierth M, Aziz A, Fritsche HM, et al. The effect of intra- and postoperative allogenic blood transfusion on patients' survival undergoing radical cystectomy for urothelial carcinoma of the bladder. *World J Urol* 2014;32:1447-53.
10. Opelz G, Sengar DP, Mickey MR, et al. Effect of blood transfusions on subsequent kidney transplants. *Transplant Proc* 1973;5:253-9.
11. Peters WR, Fry RD, Fleshman JW, et al. Multiple blood transfusions reduce the recurrence rate of Crohn's disease. *Dis Colon Rectum* 1989;32:749-53.
12. Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. *Lancet* 1985;1:941-3.
13. Gantt CL. Red blood cells for cancer patients. *Lancet* 1981;2:363.
14. Rohde JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. *JAMA* 2014;311:1317-26.
15. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. *Blood Rev* 2007;21:327-48.
16. Vamvakas EC. Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. *Transfus Med Rev* 2002;16:304-14.
17. Remy KE, Hall MW, Cholette J, et al. Mechanisms of red blood cell transfusion-related immunomodulation. *Transfusion* 2018;58:804-15.
18. Ghio M, Contini P, Ubezio G, et al. Blood transfusions with high levels of contaminating soluble HLA-I correlate with levels of soluble CD8 in recipients' plasma; a new control factor in soluble HLA-I-mediated transfusion-modulated immunomodulation? *Blood Transfus* 2014;12 Suppl 1:s105-108.
19. D'Alessandro A, Kriebardis AG, Rinalducci S, et al. An update on red blood cell storage lesions, as gleaned through biochemistry and omics technologies. *Transfusion* 2015;55:205-19.
20. Gasser O, Schifferli JA. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. *Blood* 2004;104:2543-8.
21. Juratli MA, Sarimollaoglu M, Siegel ER, et al. Real-time monitoring of circulating tumor cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry. *Head Neck* 2014;36:1207-15.
22. Kavanagh T, Buggy DJ. Can anaesthetic technique effect postoperative outcome? *Curr Opin Anaesthesiol* 2012;25:185-98.
23. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. *Cochrane Database Syst Rev* 2006;(1):CD005033.
24. Wang CC, Iyer SG, Low JK, et al. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. *Ann Surg Oncol* 2009;16:1832-42.
25. Motoyama S, Okuyama M, Kitamura M, et al. Use of autologous instead of allogeneic blood transfusion during

- esophagectomy prolongs disease-free survival among patients with recurrent esophageal cancer. *J Surg Oncol* 2004;87:26-31.
26. Kneuert PJ, Patel SH, Chu CK, et al. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. *Ann Surg Oncol* 2011;18:1327-34.
 27. Moffat LE, Sunderland GT, Lamont D. Blood transfusion and survival following nephrectomy for carcinoma of kidney. *Br J Urol* 1987;60:316-9.
 28. Linder BJ, Thompson RH, Leibovich BC, et al. The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC). *BJU Int* 2014;114:368-74.
 29. Ford BS, Sharma S, Rezaishiraz H, et al. Effect of perioperative blood transfusion on prostate cancer recurrence. *Urol Oncol* 2008;26:364-7.
 30. Heal JM, Chuang C, Blumberg N. Perioperative blood transfusions and prostate cancer recurrence and survival. *Am J Surg* 1988;156:374-80.
 31. Buchner A, Grimm T, Schneevoigt BS, et al. Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. *Scand J Urol* 2017;51:130-6.
 32. Syan-Bhanvadia S, Drangsholt S, Shah S, et al. Restrictive transfusion in radical cystectomy is safe. *Urol Oncol* 2017;35:528.e15-528.e21.
 33. Siemens DR, Jaeger MT, Wei X, et al. Peri-operative allogeneic blood transfusion and outcomes after radical cystectomy: a population-based study. *World J Urol* 2017;35:1435-42.
 34. Morgan TM, Barocas DA, Chang SS, et al. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. *Urol Oncol* 2013;31:871-7.
 35. Soubra A, Zabell JR, Adejoro O, et al. Effect of perioperative blood transfusion on mortality for major urologic malignancies. *Clin Genitourin Cancer* 2015;13:e173-181.
 36. Kluth LA, Xylinas E, Rieken M, et al. Impact of perioperative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *BJU Int* 2014;113:393-8.
 37. Lee JS, Kim HS, Jeong CW, et al. The prognostic impact of perioperative blood transfusion on survival in patients with bladder urothelial carcinoma treated with radical cystectomy. *Korean J Urol* 2015;56:295-304.
 38. Vetterlein MW, Gild P, Kluth LA, et al. Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study. *BJU Int* 2018;121:101-10.
 39. Abel EJ, Linder BJ, Bauman TM, et al. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? *Eur Urol* 2014;66:1139-47.
 40. Moschini M, Dell'Oglio P, Capogrosso P, et al. Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. *Clin Genitourin Cancer* 2015;13:562-7.
 41. Moschini M, Bianchi M, Rossi MS, et al. Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. *Urol Oncol* 2016;34:256.e7-256.e13.
 42. Moschini M, Soria F, Abufaraj M, et al. Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. *Clin Genitourin Cancer* 2017;15:e681-8.
 43. Sadeghi N, Badalato GM, Hruby G, et al. The impact of perioperative blood transfusion on survival following radical cystectomy for urothelial carcinoma. *Can J Urol* 2012;19:6443-9.
 44. Wang YL, Jiang B, Yin FF, et al. Perioperative Blood Transfusion Promotes Worse Outcomes of Bladder Cancer after Radical Cystectomy: A Systematic Review and Meta-Analysis. *PloS One* 2015;10:e0130122.
 45. Cata JP, Lasala J, Pratt G, et al. Association between Perioperative Blood Transfusions and Clinical Outcomes in Patients Undergoing Bladder Cancer Surgery: A Systematic Review and Meta-Analysis Study. *J Blood Transfus* 2016;2016:9876394.

doi: 10.21037/amj.2020.02.03

Cite this article as: Zamboni S, Lonati C, Palumbo C, Marconi MC, Mondini F, Lattarulo M, Moschini M, Cristinelli L, Belotti S, Simeone C. The effect of perioperative blood transfusion on oncological outcomes in radical cystectomy patients: a narrative review. *AME Med J* 2020;5:18.